Get the Stockscreener App
208.86
2.53%
5.19
Icon Plc stock is traded at $208.86, with a volume of 826.94K.
It is up +2.53% in the last 24 hours and down -27.65% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$203.67
Open:
$204.84
24h Volume:
826.94K
Relative Volume:
0.76
Market Cap:
$16.15B
Revenue:
$8.31B
Net Income/Loss:
$747.89M
P/E Ratio:
33.69
EPS:
6.2
Net Cash Flow:
$1.23B
1W Performance:
+4.40%
1M Performance:
-27.65%
6M Performance:
-34.31%
1Y Performance:
-22.96%
1-Day Range:
$204.00
$210.07
1-Week Range:
$183.38
$210.07
52-Week Range:
$183.38
$347.72
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ICLR | 208.71 | 16.15B | 8.31B | 747.89M | 1.23B | 6.20 |
| TMO | 510.17 | 195.55B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 231.75 | 166.92B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 131.32 | 36.94B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 195.26 | 35.03B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 413.41 | 33.80B | 3.84B | 866.24M | 792.60M | 9.80 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Should You Retain Your Conviction in Icon Plc (ICLR)? - Yahoo Finance
Prudential expands preferred healthcare network in partnership with Icon Cancer Centre - Media OutReach
ICON Plc stock hits 52-week low at $208.38 amid market shifts - Investing.com India
ICON to Present at London Healthcare Conference - TipRanks
ICON plc to Present at the Jefferies London Healthcare Conference - Business Wire
RNA Therapy Clinical Trials Market Size, Scope and Growth to 2031 - InsightAce Analytic
Rose Kidd, ICON – Winner of WMB Businesswoman Award 2024 - Women Mean Business
Icon PLC (ICLR) Shares Up 3.48% on Nov 6 - GuruFocus.com
Life Sciences BPO Market Set to Witness Significant Growth by 2024-2031:Catalent, Inc., Covance, Inc., Fareva, - EIN News
Icon (FRA:IJF) GF Value Rank : 10 (As of Nov. 04, 2024) - GuruFocus.com
ICON Plc stock touches 52-week low at $219.87 amid market shifts - Investing.com Australia
Icon PLC (ICLR) Trading 3.72% Higher on Oct 2 - GuruFocus.com
ICON's SWOT analysis: CRO giant faces headwinds amid industry shifts - Investing.com
ICON's $650 Million Power Play: Can This Bold Move Reverse a 21% Stock Plunge? - Yahoo Finance UK
ICON perks up after $250M share buyback - MSN
Baird Downgrades ICON Public Limited (ICLR) - MSN
Icon plc Strengthens Investor Confidence with Secured Notes - TipRanks
Earnings call: ICON PLC faces headwinds, eyes strategic growth By Investing.com - Investing.com Australia
Earnings call: ICON PLC faces headwinds, eyes strategic growth - Investing.com India
Icon Earnings: Shares Tank as Elevated Cancellations Reduce 2024 Guidance - Morningstar
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
FY2024 EPS Estimates for ICON Public Decreased by Analyst - MarketBeat
Pharmaceutical Contract Sales Outsourcing (CSO) Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Cha - GuruFocus.com
ICON Plc stock touches 52-week low at $227.56 amid market shifts - Investing.com Australia
U.S. Markets Finished Mixed Thursday As Tesla Led, Icon PLC Lagged - Barron's
ICON stock slips after guidance cut (ICLR:NASDAQ) - Seeking Alpha
Icon PLC Down Over 19%, on Pace for Largest Percent Decrease Since March 1999 — Data Talk - Morningstar
ICON Plc stock touches 52-week low at $227.56 amid market shifts By Investing.com - Investing.com South Africa
Icon shares maintain Outperform rating with Leerink despite market pressures - Investing.com
Baird downgrades ICON plc stock, slashes outlook on lower earnings and revenue guidance - Investing.com
S&P 500 Futures Up in Premarket Trading; Icon PLC, Darling Ingredients Lag - Barron's
ICON revenue slumps 1.2% to USD 2,030M in Q3 2024 - Medical Buyer
Icon PLC: Q3 Earnings Snapshot - Houston Chronicle
Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates - Yahoo Finance
ICON Reports Third Quarter 2024 Results - sharewise
ICON Reports Mixed Q3 Results, Secures Key Partnership - TipRanks
Icon PLC: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
ICON plc shares tumble as Q3 results miss estimates, guidance cut - Investing.com Australia
ICON plc shares tumble as Q3 results miss estimates, guidance cut By Investing.com - Investing.com South Africa
Imaging CRO Market Is Booming Worldwide 2025-2030 | WORLDCARE - openPR
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Randomization and Trial Supply Management Market 2024-2031- Calyx, Almac, ICON plc, Trialogics, IBM, Medpace CRO, Endpoi – IndiaPolitics.com - IndiaPolitics.com
Redburn Atlantic Initiates Coverage of ICON Public Limited (ICLR) with Neutral Recommendation - Nasdaq
ICON plc stock faces Neutral rating as analyst flags downside risk to growth projections - Investing.com Australia
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
4.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):